$569 Million is the total value of Fairmount Funds Management LLC's 27 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| COGT | COGENT BIOSCIENCES INC | $41,164,000 | +65.4% | 2,758,975 | 0.0% | 7.24% | +27.0% | |
| NBIX | NEUROCRINE BIOSCIENCES INC | $30,057,000 | +9.0% | 283,000 | 0.0% | 5.28% | -16.3% | |
| ARGX | ARGENX SEsponsored adr | $25,958,000 | -6.8% | 73,526 | 0.0% | 4.56% | -28.4% | |
| ENTA | ENANTA PHARMACEUTICALS INC | $24,341,000 | +9.7% | 469,264 | 0.0% | 4.28% | -15.7% | |
| TYRA BIOSCIENCES INC | $12,455,000 | +22.9% | 1,416,998 | 0.0% | 2.19% | -5.6% | ||
| ACAD | ACADIA PHARMACEUTICALS INC | $12,300,000 | +16.1% | 751,804 | 0.0% | 2.16% | -10.8% | |
| KROS | KEROS THERAPEUTICS INC | $10,251,000 | +36.2% | 272,498 | 0.0% | 1.80% | +4.6% | |
| ASTRIA THERAPEUTICS INC | $8,242,000 | +201.4% | 911,736 | 0.0% | 1.45% | +131.5% | ||
| AMRN | AMARIN CORP PLCspons adr new | $6,087,000 | -26.8% | 5,584,837 | 0.0% | 1.07% | -43.8% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $3,732,000 | -13.2% | 389,588 | 0.0% | 0.66% | -33.3% | |
| TIL | INSTIL BIO INC | $3,262,000 | +4.8% | 673,905 | 0.0% | 0.57% | -19.5% | |
| ALLK | ALLAKOS INC | $901,000 | +95.4% | 147,189 | 0.0% | 0.16% | +49.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.